Literature DB >> 16451208

The association between HLA class II haplotype with Graves' disease in Thai population.

T Wongsurawat1, J Nakkuntod, P Charoenwongse, T Snabboon, V Sridama, N Hirankarn.   

Abstract

The distribution of HLA-DRB1, -DQA1 and -DQB1 alleles were analysed in 124 Graves' disease (GD) patients compared to 124 normal controls in order to identify the alleles/haplotypes associated with GD in Thai population. The DRB1*1602-DQA1*0102-DQB1*0502 haplotype was significantly increased in GD patients (P = 0.0209, OR = 2.55). DRB1*07-DQA1*0201-DQB1*0201 haplotype (P = 0.039, OR = 0.32) and HLA-DRB1*12-DQA1*0601-DQB1*0301 haplotype (P = 0.0025, OR = 0.28) were significantly decreased in GD patients. Interestingly, a protective DRB1*07 allele in Thai population lacks an arginine at position 74 similar to DRB1*0311 (a protective allele in Caucasians). A significant association of DRB1*1602-DQA1*0102-DQB1*0502 and HLA-DRB1*12-DQA1*0601-DQB1*0301 alleles and haplotypes with GD was recently reported in Korean but not in any Caucasian studies. Thus, DRB1*1602 allele and closely linked haplotype, DRB1*1602-DQA1*0102-DQB1*0502, might serve as a marker for genetic susceptibility to GD in Asian population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451208     DOI: 10.1111/j.1399-0039.2005.00498.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  9 in total

1.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies.

Authors:  Owen D Solberg; Steven J Mack; Alex K Lancaster; Richard M Single; Yingssu Tsai; Alicia Sanchez-Mazas; Glenys Thomson
Journal:  Hum Immunol       Date:  2008-06-09       Impact factor: 2.850

3.  Actual Associations between HLA Haplotype and Graves' Disease Development.

Authors:  Katarzyna Zawadzka-Starczewska; Bogusław Tymoniuk; Bartłomiej Stasiak; Andrzej Lewiński; Magdalena Stasiak
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

4.  Association of HLA DQ B1* and HLA DR B1* alleles with goitrous juvenile autoimmune hypothyroidism--a case control study.

Authors:  P L Rekha; Vijayalakshmi Valluri; Shilpa S Rakh; Vinod Pantula; M Ishaq
Journal:  J Clin Immunol       Date:  2007-06-22       Impact factor: 8.317

Review 5.  Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms.

Authors:  Amanda Huber; Francesca Menconi; Sarah Corathers; Eric M Jacobson; Yaron Tomer
Journal:  Endocr Rev       Date:  2008-09-05       Impact factor: 19.871

6.  Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles.

Authors:  Pei-Lung Chen; Cathy Shen-Jang Fann; Chen-Chung Chu; Chien-Ching Chang; Su-Wei Chang; Hsin-Yi Hsieh; Marie Lin; Wei-Shiung Yang; Tien-Chun Chang
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

7.  Immunogenetic mechanisms leading to thyroid autoimmunity: recent advances in identifying susceptibility genes and regions.

Authors:  Oliver J Brand; Stephen C L Gough
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

8.  HLA-DRA Gene Polymorphisms Are Associated with Graves' Disease as an Autoimmune Thyroid Disease.

Authors:  Peng Du; Jiaoli Zhu; Qiuming Yao; Tiantian Cai; Jianbin Xu; Yudie Fang; Yuqing Wu; Wen Zhang; Jin-An Zhang
Journal:  Biomed Res Int       Date:  2022-09-12       Impact factor: 3.246

9.  Human leucocyte antigen alleles confer susceptibility and progression to Graves' ophthalmopathy in a Southern Chinese population.

Authors:  Xiaosheng Huang; Guiqin Liu; Zhihui Deng; Jun Zhao; Shaoyi Mei; Jiamin Cai; Jing Rao; Minzhong Tang; Tianhui Zhu; Wenchiew Chen; Shiming Peng; Yan Wang; Ye Ye; Tong Zhang
Journal:  Br J Ophthalmol       Date:  2020-11-21       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.